The predictive value of immunoscore in patients with hepatocellular carcinoma
【摘要】：Purpose: The increasing evidences demonstrated that immunoscore(IS) has an advantage over or may compensate for the currently used tumour staging methods in a variety of tumours; however, IS in hepatocellular carcinoma(HCC) remains unreported. Experimental Design: IS was performed on serial sections from two HCC cohorts(n=90; n=359; total 449) and compared with current tumour staging methods. Results: In both cohorts, although positive correlations existed between the CD3+ or CD8+ cells in tumour tissue and OS, a large variation existed in the use of one immune cell as an indicator. We investigated whether the combined analysis(e.g. IS) could improve the prediction. The patients were divided into CD3 Hi Hi plus CD8 Hi Hi group(IS=4, the highest score), CD3 Lo Lo plus CD8 Lo Lo group(IS=0, the lowest score) and intermediates(IS=1-3). Our results demonstrated that the IS of 359 HCC sections could be divided into four groups: IS-0(n=143), IS-1(n=68), IS-2(n=95), IS-3(n=29) and IS-4(n=24). A strong association was identified between a higher IS(IS≧2) and longer survival. When we used IS-2 as a cut-off value, the TNM-Ⅰ or Ⅲ and BLCL-A, B or C stage patients could be divided into two groups: the patients with IS≥2 in each stage clearly exhibited longer survival compared with the same stage patients with IS2. In addition, it was noted that patients with higher IS exhibited a lower rate of tumour relapse and thrombus, and smaller tumour size, and lower serum level of AST and AFP. Conclusion: These findings suggest IS is a promising prognostic and predictive indicator for classification of HCC.